Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
1. To determine if levofloxacin given prophylactically during periods of neutropenia to patients being treated for AL or undergoing SCT will decrease the incidence of bacteremia
2. To determine the effect of prophylaxis on the incidence of F+N, severe infection and death from bacterial infection
3. Assess safety, with specific focus on musculoskeletal disorders
4. Assess impact on bacterial resistance
For further information on this clinical trial, please contact us at 732-235-8675 or email@example.com.
Copyright ©2016 Rutgers, The State University of New Jersey, all rights reserved
Rutgers Cancer Institute of New Jersey is the state's only National Cancer Institute-designated Comprehensive Cancer Center
The information contained in this website is not a substitute for medical consultation. A physician should always be consulted for any health problem or medical condition.